Stiff Person Breakthrough: CAR T Therapy Restores Walking

Stiff Person Breakthrough results from a year-long trial suggest that a single infusion of reprogrammed immune cells can change the course of a rare and disabling neurological disease. Patients who received the experimental CAR T treatment completed a walking test in nearly half the time they needed before treatment, and most no longer required ongoing immune-suppressing drugs a year later, according to researchers at the University of Colorado Anschutz Medical Campus.

Stiff person syndrome, usually shortened to SPS, is a progressive autoimmune condition in which the body's immune system attacks the nervous system, causing rigid muscles, painful spasms and growing difficulty walking. An estimated four in five patients eventually need a walking aid or a wheelchair, and no treatment approved specifically for the condition exists today. Current care mostly manages symptoms or dampens immune activity on an ongoing basis, which means patients live with both the disease and the burden of continuous medication.

What the one-year results show

The phase two trial, sponsored by Kyverna Therapeutics and led by principal investigator Amanda Piquet, followed 26 patients for a full year after one infusion of the therapy, known by the short name miv-cel. Every participant completed the year of follow-up, giving researchers a complete picture of whether early gains lasted. The headline measure was a timed walk over a short course: patients finished it in a median of 49 percent less time than before treatment, a gain the team described as comparable to the pace of typical healthy adults for more than a third of the group.

The practical changes behind that number matter as much as the number itself. Of a dozen participants who had needed a walking aid for the test at the start, eight walked it unaided at one year. Muscle stiffness eased, sensitivity to sudden stimuli fell, and overall disability scores improved across the group. Perhaps most striking, nearly all participants remained free of immune-suppressing or immune-modifying treatment for SPS at the one-year mark, even though the immune cells targeted by the therapy had begun returning in about two-thirds of them. That pattern suggests the treatment may reset something in the underlying disease rather than merely masking symptoms while the targeted cells are gone, according to the trial team, as reported by MedicalXpress.

Why a single treatment may keep working

The therapy starts with the patient's own immune cells, which are collected and modified in a laboratory so they seek out the B cells that help drive the autoimmune attack. Once returned to the patient, those engineered cells do their work and then fade, which is why a one-time infusion can plausibly produce lasting change. That logic already transformed blood cancer care, where CAR T treatments are established, but no such therapy has yet been approved for an autoimmune disease. If regulators agree, this one would be the first, and the first treatment approved specifically for SPS at all.

That distinction explains why specialists beyond the trial team are watching closely. A therapy that works once, rather than every week or month, would spare patients repeated infusions, clinic visits and the side effects of long-term immune suppression. It would also give researchers a template: the same approach is already being tested in other B-cell-driven conditions, including generalized myasthenia gravis and forms of multiple sclerosis, where the immune system likewise turns on the body's own tissues. Success in one rare disease could therefore reshape how doctors think about several others.

What happens next, and what is still unproven

The company behind the therapy has said it intends to complete its rolling application for approval with the US Food and Drug Administration in the final quarter of this year, and the one-year data were presented at an international neurology conference in Toronto. Regulators will weigh the durability of the benefit, the safety record across a larger group, and whether the gains hold beyond a single year. A small trial, however encouraging, cannot answer every question: longer follow-up will show whether walking gains persist, whether any late side effects emerge, and which patients benefit most.

There is also the question of access. Even an approved therapy helps only the patients who can reach it, and cell therapies are complex to deliver, requiring specialized centres and careful patient selection. Pricing, coverage and manufacturing capacity will all shape who actually benefits, and none of those details is settled yet. For now, patients should not read the findings as an available treatment or a reason to change current care; the therapy remains experimental until regulators decide.

Still, for a community that has waited years for a treatment aimed at the disease itself rather than its symptoms, the results mark a turning point. Recent coverage of experimental medicine has shown both sides of that coin: a new explanation for why a promising class of cancer drugs caused harsh side effects illustrates how biology can stall a field, while a drug approval offering surgery-free hope shows what happens when the science finally lines up. Laboratory work such as heart cells grown stronger in lab tests reminds readers that the path from bench to bedside is long. The Stiff Person Breakthrough now joins that story as a rare case where the path suddenly looks shorter.